#Emtriva

Antiretroviral therapy for HIV, also effective against HBV, lowers the risk of developing chronic hepatitis.

Two cases suggest that Viread alone may not be enough to prevent HIV through pre-exposure prophylaxis (PrEP)

Among HIV-positive people, it is preferable to treat hepatitis B with a two-drug regimen rather than with monotherapy.

Viread (tenofovir) is highly effective at suppressing hepatitis B, even after an eight-year period.

Early results of Merck’s combination hepatitis C therapy showed comparable safety between those with or without HIV, plus near-perfect cure ra...

The HIV antiretroviral Viread (tenofovir) is highly effective in combating both HIV and hepatitis B among those coinfected with both viruses

The HIV antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine), can suppress hepatitis B in three-quarters of those with ?immune-toler...

About 12 percent of HIV-positive people with chronic hepatitis B virus (HBV) infection failed to control their HBV after one year with Viread...

The U.S. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has come nearly full circle...